Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NCT04400331 Phase 3 ACTIVE_NOT_RECRUITING

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Details

Lead sponsor	Neurocrine Biosciences
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	154
Start date	2020-09-18
Completion	2026-03

Conditions

• Chorea, Huntington

Interventions

• Valbenazine

Primary outcomes

• Number of Participants with Treatment-Emergent Adverse Events (TEAEs) — Up to 262 weeks

Countries

United States, Canada